Friday, July 10, 2026

pharma · Interstitial Lung Disease (ILD) · Gastrointestinal Disease

ZhongShan Hospital, Fudan

Shanghai Zhongshan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Interstitial Lung Disease (ILD), Gastrointestinal Disease, Takayasu Arteritis. NovaPharmaNews links 3 clin

CN HQ
1936 Founded
624 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
1936
Employees
624
Programs
3
Drugs
8
Patents
0
Clinical program

ACE001-RI001

Phase 1 · mab · Interstitial Lung Disease (ILD)

ACE001-RI001 for Interstitial Lung Disease (ILD) is a Phase 1 program (mab) at Shanghai Zhongshan Hospital with 1 ClinicalTrials.gov record(s).

Internal code ACE001-RI001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Shanghai Zhongshan Hospital
Phase
Phase 1
Modality
mab
Indication
Interstitial Lung Disease (ILD)
Status
active
Trials
1